According to a company official, the findings indicate the role of polyfunctional T cells in CAR T efficacy and the usefulness of single-cell protein analysis.
A new study suggests that enhanced tumor clone frequencies, found by T cell receptor beta gene sequencing, coincide with poorer mycosis fungoides outcomes.
An exome- and expression-based analysis of 304 DLBCL cases led to five molecular subtypes, offering insights into disease pathogenesis and treatment outcomes.
The group now plans to run the 32-gene panel in clinical trials to demonstrate its utility and make the case for offering it within Canada's healthcare system.
The two companies are entering a partnership to introduce diagnostic tests using NanoString's nCounter technology in Japan, beginning with a lymphoma assay.
A GWAS and meta-analysis linked Hodgkin lymphoma risk to variants in sequences related to B cell development, immune function, and autoimmune disease risk.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
The company said it plans to use the proceeds raised in the private placement primarily to fund its Hodgkin's lymphoma test clinical trial.
In Science this week: two proteins may help treat muscular dystrophy, and more.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.